Sveriges mest populära poddar
The BioCentury Show
VetenskapLife Science

Ep. 112 - Chris Arendt on rebuilding Takeda for AI

40 min•18 juni 2026

Chris Arendt, CSO of Takeda, likens the AI overhaul at the pharma to gutting and rebuilding an old house, from the plumbing and electrical up, while you’re still living there. In a Fireside Chat at Grand Rounds U.S. in Seattle, Arendt sat down with Editor in Chief Simone Fishburn to discuss how Takeda is integrating AI across R&D, in and beyond the science, while still executing on the active programs in drug development.

View full story: https://www.biocentury.com/article/659807

#ArtificialIntelligence #PharmaInnovation #DrugDevelopment #DigitalTransformation #ResearchAndDevelopment

00:00 - Introduction
02:07 - Revamping Takeda for AI
19:03 - Teams & Talent
26:43 - Alliances
32:50 - Q&A

Fler avsnitt av The BioCentury Show

Visa alla avsnitt av The BioCentury Show
Ep. 113 - Frank Jiang on Hengrui’s rise and China’s new era of biopharma dealmaking
•35 min
Ep. 111 - McGill's Angela Genge on why ALS drug development is turning a corner
•37 min
Ep. 110 - Richard Pops on Three Decades in Biotech: Drug pricing, FDA and China
•38 min
Ep. 109 - Mind the Gap: Karen Knudsen on Fixing Cancer Drug Development
•36 min
Ep. 108 - Rethinking Discovery: Chris Hollowood on Causal Biology and Syncona’s Strategy
•33 min
Ep. 107 - Forbion’s Slootweg on Europe Biotech, NewCos From Asia and Green Investing
•38 min
Ep. 106 - Can the U.K. Capture Biotech Value? Daniel Mahony on Growth, Pricing and Reform
•34 min
Ep. 105 - Recursion’s Najat Khan: AI Will Be Judged by the Medicines It Delivers
•40 min
Ep. 104 - SoftBank’s Jacqueline Fok on AI Drug Development, Metsera and the U.K. Biotech Opportunity
•35 min
Ep. 103 - Kolchinsky: FDA Conservatism, MFN and IRA Are Slowing Drug Development
•41 min

The BioCentury Show med BioCentury finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.